Oral Cancer Diagnostics Market Research Report Information by Indication (Oral Squamous Cell Carcinoma, Oral Verrucous Carcinoma, Mucoepidermoid Carcinoma, Oral Cavity Lymphomas), Diagnosis Type (Endoscopy, Biopsy, X-Ray and Computed Tomography (CT), Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), Ultrasonography, Fluorescence Imaging), End User (Hospitals and Clinics, Research and Academic Institutes) - Forecast till 2032

Oral Cancer Diagnostics Market Overview

The Oral Cancer Diagnostics Market is anticipated to reach USD 2.98 Billion by 2032 at 4.8% CAGR during the forecast period 2023-2032. Condition of oral cancer includes cancer in tongue, lips, soft and hard palate, cheeks, the floor of mouth, sinuses, and pharynx. Its treatment of oral cancer largely depends upon the stages. So, early diagnosis of oral cancer is very important that makes it easier for treatment.

Rising aids of proper healthcare, efficiency for detecting oral cancer, technological advancements, increasing number of people who have oral cancer are some factors that are expected to influence the growth of the market. Although higher health costs, unavailability of adequate healthcare facilities, and fewer trained professionals are estimated to hinder the growth of the oral cancer diagnostics market.

COVID-19 Analysis

The outbreak of the COVID-19 pandemic has massively impacted the oral cancer diagnostics market. It has disrupted healthcare facilities, especially in underdeveloped countries in Africa and other developing countries. It has prevented the whole cancer diagnosis sector, such as regular tests and screenings, ramification, follow-ups of patients, etc. The infection and disruption caused by COVID-19 have spiked the health risks of cancer patients.

Oral Cancer Diagnostics Market Trends

Drivers

Since recent past years, oral cancer diagnostics have been gaining importance due to the increasing number of cases in the sector of oral cancer. As per reports by the National Institutes of Health (NIH), which was published in 2017, it was estimated that around 3,70,309 people had pharynx cancer and oral cavity. Also, around 3% of the population registered newly reported increasing cases of the pharynx and oral cancer annually. Hence, the continuous growing pervasiveness for oral cancer largely led to the increased technological advancements for better facilities, diagnostic tools that have influenced the market growth. Furthermore, increasing consumption of tobacco, consumption of alcohol, and HPV-induced cancers are some major drivers of the market.

Restraints

Oral cancer constitutes the largest share among the affected patients suffering from various types of cancer. The mortality rate caused by oral cancer is comparatively high due to a lack of proper tests to detect the disease at an early stage. Detecting oral cancer in an early stage can largely affect the treatment in a positive way. Furthermore, the present conventional tests in the market take more time and incur higher costs which are a major restraint in oral cancer diagnostics.

Challenges

Technological development, such as the usage of biosensors, has helped manufacturing companies to improve their functions. Also, the development of befitting biomarkers essential for the rapid test of oral cancer is loaded with several challenges to fulfill the sensitiveness and specification requirements.

Opportunities

Many companies are trying to improve the testing methods and equipment needed during routine tests among cancer-affected people. They are developing equipment called Oral Cancer Rapid Testing Kit or OCRTK. This equipment is capable of detecting oral cancer is lesser time and in an effective way. Technological advancement and innovation of new and convenient products will lead the global oral market. The requirement comprises RNA, lipids, exosomes, and DNA. The emergence of new technologies that boost immunity has increased the opportunity to develop oral cancer tests.

Cumulative Growth Analysis

The increasing cases of oral cancer among people worldwide have significantly increased the importance of oral cancer diagnostics. Several technological developments, such as the innovation of oral cancer rapid test kits are attracting more consumers in recent past years. It is anticipated that the global oral testing kits will register a compound growth annual rate (CAGR) of 6.94%. The market is expected to reach about USD 736.90 Million during the forecast period 2018-2024.

Value Chain Analysis

Oral cancer diagnostics are used to detect cancer occurred in the tongue, lips, cheeks, and pharynx. Rapid invention and development of rapid test kits to detect the cancer earlier than the present devices are used worldwide. The invention of rapids kits will help to cater more consumers for its efficient and time-effective use in forthcoming years.

Oral Cancer Diagnostics Market Segment Insights

The global oral cancer diagnostic market is segmented into diagnosis type, indication, and user end.

By indication, the oral cancer diagnosis market based on diagnosis type is divide into biopsy, X-ray, positron emission tomography (PET), computed tomography, and others.

By diagnosis type- the global oral cancer diagnosis market is segmented into biopsy, endoscopy, computed tomography (C.T.), X-ray, ultrasonography, magnetic resonance imaging (MRI), fluorescence imaging, positron emission tomography (PET), and others.

By end-user- the oral cancer diagnostics market by end-user is segmented into clinics and hospitals and academic and research institutes.

Regional Analysis

Geographically, the oral cancer diagnostics market is segmented into the Americas, Asia-Pacific, Europe, the Middle East, and Africa.

The North and South America region is evaluated to dominate the oral cancer diagnostics market during the forecast period. The presence of several key market players, increasing oral cancer cases, well-developed and advanced technologies, and supportive government policies in developed countries like Canada and the U.S.

The Asia-Pacific is anticipated to experience rapid growth in the oral cancer diagnostics market due to rapid development in the medical field, increasing population, diagnostic modalities, increasing awareness about cancer-related diseases, and support of expenditure by the government in the healthcare sector. In the year 2018, developing countries like India accounted for about 34.34% in the global market of oral cancer diagnostics in the Asia-Pacific region.

The global European market is evaluated to have a significant growth in the oral cancer diagnostics market due to increasing development and support from the government, investments from major key players for research and developments, increasing usage of adequate medical diagnostics for appropriate ad accurate treatments of cancerous diseases. In 2018, as per the reports published by the World Health Organisation (WHO) emergence of new cancer cases of around 61,885 along with 24063 deaths occurred due to oral cancer in the European region.

The oral cancer diagnostics market in the Middle East and African region is anticipated to grow faster than other geographical regions. Gradual increase in adopting innovative and technologically advanced equipment and growth in the awareness about cancer-related treatments is primary reasons for the growth of oral cancer diagnostic.

Competitive Landscape

Many key players try to dominate the oral cancer diagnostics market by expanding their business across the world. They use various strategies such as acquisitions, mergers, collaborations, joint ventures, introducing new efficient products in the market, etc. Companies like Thermo Fisher Scientific, Siemens Healthineer, Hitachi, and G.E. Healthcare collaborate with different companies to expand their business portfolio. For example, a company called Canon Medical Systems Corporation announced its acquisition of all the shares of Skope magnetic Resonance Technologies to expand its business portfolio. Here is the list of companies-

• 
  Thermo Fisher Scientific Inc. (U.S.)


• Hoffmann-La Roche Ltd (Switzerland)


• Vigilant Biosciences, Inc. (U.S.)


• Koninklijke Philips NV (Netherlands)


• Hitachi Ltd (Japan)


• 
  Philips NV (Netherlands)


• QIAGEN (Germany)


• E. Healthcare (U.S.)


• Recent Developments


• Koninklijke Philips NV (Netherlands)


• PeriRx, LLC (U.S.)

Recent Developments-

In 2018, G.E. Healthcare announced its business expansion by partnering with F. Hoffman La Roche to develop an integrated diagnostics platform for oncology.

In 2019, Hitachi announced the approval from Food and Drug Administration (FDA) for its new technology Lumina 3 Tesla (3T) MRI scanner.

Report Overview

The global market of oral cancer diagnostics provides different information and information regarding the forecast. Some of the information includes market drivers, restraints, challenges, competitive landscape, and regional analysis. Moreover, the report gives an analytical representation of oral cancer diagnostics, such as investments in research and development, market trends, opportunities, etc. The information provided in this report is collected from primary and secondary sources.

Oral Cancer Diagnostics Market Segmentation

Study Period2021-2027

Base Year2021

Forecast Period2021-2027

Historical Period2020-2021

Oral Cancer Diagnostics Diagnosis Outlook

• Ultrasonography


• Magnetic Resonance Imaging (MRI)


• X-Ray


• Computed Tomography (C.T.) Scan


• Positron Emission Tomography (PET)


• Fluorescence Imaging


• Computed Tomography (C.T.) Scan


• Endoscopy


• Others

Oral Cancer Diagnostics Indication Outlook

• Oral Verrucous Carcinoma


• Oral Squamous Cell Carcinoma


• Mucoepidermoid Carcinoma (Salivary Gland)


• Oral Cavity Lymphomas


• Others

Oral Cancer Diagnostics End-User Outlook

• Research and Academic Institutes


• Hospitals and Clinics


• Others

Oral Cancer Diagnostics Geographical Region Outlook

• North America (The U.S. and Canada)


• Latin America (Mexico, Brazil, and rest)


• Asia Pacific (India, Japan, China, Australia, and rest)


• Europe (Germany, France, Spain, Italy, U.K.)


• The Middle East and Africa (GCC, South Africa, and rest)